Base de dados : MEDLINE
Pesquisa : Adenoma and De and Ducto and Biliar [Palavras]
Referências encontradas : 4336 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 434 ir para página                         

  1 / 4336 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29277822
[Au] Autor:Bruckner HW; Gurell D; Hirschfeld A
[Ad] Endereço:MZB Foundation for Cancer Research, New York, NY, U.S.A. bruckneroncology@gmail.com.
[Ti] Título:Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
[So] Source:Anticancer Res;38(1):547-552, 2018 01.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:BACKGROUND/AIM: Bevacizumab (bev), when added to a moderate dose combination of previously failed cytotoxins, as a third- and fourth-line therapy for refractory gastric, cholangiocarcinoma, and ovarian cancers, produced high-quality responses. The regimen was based on preclinical models designed in order to simultaneously partner both bev and each of the cytotoxins with 4-5 synergistic drugs. PATIENTS AND METHODS: Eligible patients (n=9) had high-grade endometrial tumors and had failed standard chemotherapy. Bev (10 mg/kg every 2 weeks) and cyclophosphamide (150-250 mg/m ), were added to a combination of gemcitabine, fluorouracil, leucovorin, irinotecan and a platinum analogue -first without and then with docetaxel- each at approximately 1/2 to 1/3 of their standard dosage. Dose modification aimed at a repeated absolute neutrophil count (ANC) of 750-1,500 µl or platelets of 125,000-75,000 µl. Safety measures included stop-go use (intermittent, as needed, brief withholding of bev with resumption when again tolerated), of bev, and both prospective and ongoing dose modification in order to protect the bowels. RESULTS: Induction treatment was free of life-threatening complications. Nine consecutive patients, 3 under second- and 6 under multi-line treatment, had 9 objective responses and 8 produced long clinical benefits, 2 of which were complete responses. Seven responses created opportunities for personalized added treatment and research. Absolute median survival was 21.5 months for the 8 patients with platinum-resistant tumors. One patient was unable to tolerate a first standard adjuvant dose of paclitaxel. After rapid peritoneal progression of disease, treatment has produced 52+ months of unmaintained complete remission. CONCLUSION: Bev, in the combination that was used in this study, meets response, survival, and toxicity criteria for further testing against second- or multi-line chemotherapy-resistant tumors and also when a standard treatment is not safe.
[Mh] Termos MeSH primário: Antineoplásicos Imunológicos/uso terapêutico
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico
Bevacizumab/uso terapêutico
Neoplasias dos Ductos Biliares/tratamento farmacológico
Colangiocarcinoma/tratamento farmacológico
Neoplasias do Endométrio/tratamento farmacológico
Neoplasias Ovarianas/tratamento farmacológico
[Mh] Termos MeSH secundário: Adenocarcinoma/tratamento farmacológico
Camptotecina/análogos & derivados
Camptotecina/uso terapêutico
Cisplatino/uso terapêutico
Desoxicitidina/análogos & derivados
Desoxicitidina/uso terapêutico
Feminino
Fluoruracila/uso terapêutico
Seres Humanos
Quimioterapia de Indução/métodos
Leucovorina/uso terapêutico
Meia-Idade
Estudos Retrospectivos
Taxoides/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Immunological); 0 (Taxoids); 0W860991D6 (Deoxycytidine); 15H5577CQD (docetaxel); 2S9ZZM9Q9V (Bevacizumab); 7673326042 (irinotecan); B76N6SBZ8R (gemcitabine); Q20Q21Q62J (Cisplatin); Q573I9DVLP (Leucovorin); U3P01618RT (Fluorouracil); XT3Z54Z28A (Camptothecin)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180104
[Lr] Data última revisão:
180104
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171227
[St] Status:MEDLINE


  2 / 4336 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28679985
[Au] Autor:Ozawa N; Doi S; Tsujikawa T; Mabuchi M; Kajiyama Y; Sato K; Kikuchi K; Takahashi M; Kawamoto M; Yasuda I
[Ad] Endereço:Department of Gastroenterology, Teikyo University Mizonoguchi Hospital.
[Ti] Título:Intrahepatic cholangiocarcinoma producing granulocyte colony-stimulating factor and parathyroid hormone-related protein.
[So] Source:Nihon Shokakibyo Gakkai Zasshi;114(7):1285-1292, 2017.
[Is] ISSN:0446-6586
[Cp] País de publicação:Japan
[La] Idioma:jpn
[Ab] Resumo:A 78-year-old man was referred to our hospital with suspected liver abscess. Fever and inflammatory reaction resolved after percutaneous drainage and administration of antibiotics. However, leukocyte count was remarkably increased, and hypercalcemia was noted. The liver mass was also enlarged, as observed in the follow-up abdominal CT scans. Therefore, a percutaneous needle biopsy was performed, and the histopathological findings indicated the presence of adenocarcinoma. Additional blood examination revealed high serum levels of granulocyte colony-stimulating factor (G-CSF) and parathyroid hormone-related protein (PTHrP). Lastly, the patient was diagnosed with cholangiocarcinoma producing G-CSF and PTHrP. Chemoradiotherapy with S-1 was initiated, which was partially effective. However, the patient died 134 days after initiating the therapy. Only two cases of cholangiocarcinoma producing G-CSF and PTHrP have been reported to date. Here we reported an additional case of cholangiocarcinoma producing G-CSF and PTHrP.
[Mh] Termos MeSH primário: Adenocarcinoma/diagnóstico por imagem
Neoplasias dos Ductos Biliares/diagnóstico por imagem
Colangiocarcinoma/diagnóstico por imagem
Fator Estimulador de Colônias de Granulócitos/biossíntese
Proteína Relacionada ao Hormônio Paratireóideo/biossíntese
[Mh] Termos MeSH secundário: Adenocarcinoma/complicações
Adenocarcinoma/metabolismo
Idoso
Neoplasias dos Ductos Biliares/complicações
Neoplasias dos Ductos Biliares/metabolismo
Neoplasias dos Ductos Biliares/patologia
Colangiocarcinoma/complicações
Colangiocarcinoma/metabolismo
Seres Humanos
Hipercalcemia/etiologia
Masculino
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Parathyroid Hormone-Related Protein); 143011-72-7 (Granulocyte Colony-Stimulating Factor)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170707
[St] Status:MEDLINE
[do] DOI:10.11405/nisshoshi.114.1285


  3 / 4336 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28648977
[Au] Autor:Kwon J; Kim K; Chie EK; Kim BH; Jang JY; Kim SW; Oh DY; Bang YJ
[Ad] Endereço:Department of Radiation Oncology, Seoul National University College of Medicine, Daehak-ro 101, Jongno-gu, Seoul, South Korea; Department of Radiation Oncology, Chungnam National University Hospital, Munhwaro 282, Jungku, Daejeon, South Korea.
[Ti] Título:Prognostic relevance of lymph node status for patients with ampullary adenocarcinoma after radical resection followed by adjuvant treatment.
[So] Source:Eur J Surg Oncol;43(9):1690-1696, 2017 Sep.
[Is] ISSN:1532-2157
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Attempts have been made to revise the nodal stage due to simplicity of current N staging system in ampullary adenocarcinoma. However, because of the disease rarity, there have only been a few studies assessing the prognostic impact of lymph node (LN) parameters. METHODS: We retrospectively analyzed 120 patients who underwent radical resection followed by adjuvant chemoradiotherapy for ampullary adenocarcinoma. The effect of LN parameters (number of total harvest LNs, number of metastatic LN (MLN), lymph node ratio (LNR), and log odds of positive LNs (LODDS)) on overall survival (OS), locoregional relapse-free survival (LRFS) and distant metastasis-free survival were evaluated. Cutoff points of MLN, LNR and LODDs were determined using maximal χ method. RESULTS: Fifty-seven patients (48%) were staged as pN1 and their survival was not significantly decreased compared with pN0 patients. There was also no significant difference between patients with MLN 0 vs. 1. In univariate analyses, MLN (0-1 vs. ≥2), LNR (≤17% vs. >17%) and perineural invasion were common prognosticators for OS and LRFS. Distant metastasis-free survival was not influenced by LN status. In addition, multivariate analysis revealed that among the LN parameters, LNR was able to independently predict both OS and LRFS. CONCLUSIONS: LNR performs better than other LN related parameters for predicting survival. After radical resection followed by adjuvant treatment, survival of patients with one positive LN does not seem to differ from patients without LN metastasis.
[Mh] Termos MeSH primário: Adenocarcinoma/secundário
Adenocarcinoma/cirurgia
Ampola Hepatopancreática
Neoplasias do Ducto Colédoco/patologia
Neoplasias do Ducto Colédoco/cirurgia
Excisão de Linfonodo
Linfonodos/patologia
[Mh] Termos MeSH secundário: Adenocarcinoma/tratamento farmacológico
Adulto
Idoso
Fístula Anastomótica/etiologia
Quimiorradioterapia Adjuvante/efeitos adversos
Neoplasias do Ducto Colédoco/tratamento farmacológico
Intervalo Livre de Doença
Feminino
Seres Humanos
Linfonodos/cirurgia
Metástase Linfática
Masculino
Meia-Idade
Invasividade Neoplásica
Estadiamento de Neoplasias
Nervos Periféricos/patologia
Prognóstico
Estudos Retrospectivos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170627
[St] Status:MEDLINE


  4 / 4336 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28624624
[Au] Autor:Takasawa K; Takasawa A; Osanai M; Aoyama T; Ono Y; Kono T; Hirohashi Y; Murata M; Sawada N
[Ad] Endereço:Department of Pathology, Sapporo Medical University School of Medicine, Sapporo, Japan.
[Ti] Título:Claudin-18 coupled with EGFR/ERK signaling contributes to the malignant potentials of bile duct cancer.
[So] Source:Cancer Lett;403:66-73, 2017 Sep 10.
[Is] ISSN:1872-7980
[Cp] País de publicação:Ireland
[La] Idioma:eng
[Ab] Resumo:Our recent work revealed that elevated expression of claudin-18 is involved in bile duct neoplasia. In the present study, we found that wound generation of a cell sheet de novo induced claudin-18 expression in its leading edge, coincident with high mitotic activity. We also found that the suppression of claudin-18 expression significantly reduced cell growth and invasiveness of bile duct cancer cell lines and tumorigenicity in vivo. In addition, an antibody specific to an extracellular loop of claudin-18 showed similar effects on the cells such as cell proliferation. Interestingly, treatment with epidermal growth factor (EGF) and overexpression of RAS oncogene induced claudin-18 expression by activation of extracellular signal-related kinase (ERK)1/2. Furthermore, enhanced claudin-18 expression activated ERK1/2. These findings provide evidence for an oncogenic property of claudin-18 in bile duct carcinoma cells via modulation of EGFR/ERK signaling, indicating that claudin-18 is a possible therapeutic target for this malignancy.
[Mh] Termos MeSH primário: Adenocarcinoma/enzimologia
Neoplasias dos Ductos Biliares/enzimologia
Claudinas/metabolismo
Proteína Quinase 1 Ativada por Mitógeno/metabolismo
Proteína Quinase 3 Ativada por Mitógeno/metabolismo
Receptor do Fator de Crescimento Epidérmico/metabolismo
Transdução de Sinais
[Mh] Termos MeSH secundário: Adenocarcinoma/genética
Adenocarcinoma/patologia
Animais
Neoplasias dos Ductos Biliares/genética
Neoplasias dos Ductos Biliares/patologia
Linhagem Celular Tumoral
Movimento Celular
Proliferação Celular
Tamanho Celular
Claudinas/genética
Ativação Enzimática
Retroalimentação Fisiológica
Feminino
Regulação Neoplásica da Expressão Gênica
Seres Humanos
Camundongos Endogâmicos BALB C
Camundongos Nus
Fosforilação
Domínios Proteicos
Proteína Quinase C/metabolismo
Proteínas Proto-Oncogênicas p21(ras)/genética
Interferência de RNA
Fatores de Tempo
Transfecção
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (CLDN18 protein, human); 0 (Claudins); EC 2.7.10.1 (EGFR protein, human); EC 2.7.10.1 (Receptor, Epidermal Growth Factor); EC 2.7.11.13 (Protein Kinase C); EC 2.7.11.24 (MAPK1 protein, human); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1); EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3); EC 3.6.5.2 (HRAS protein, human); EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras))
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170619
[St] Status:MEDLINE


  5 / 4336 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28524160
[Au] Autor:Strell C; Norberg KJ; Mezheyeuski A; Schnittert J; Kuninty PR; Moro CF; Paulsson J; Schultz NA; Calatayud D; Löhr JM; Frings O; Verbeke CS; Heuchel RL; Prakash J; Johansen JS; Östman A
[Ad] Endereço:Department of Oncology-Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet, Stockholm 17176, Sweden.
[Ti] Título:Stroma-regulated HMGA2 is an independent prognostic marker in PDAC and AAC.
[So] Source:Br J Cancer;117(1):65-77, 2017 Jun 27.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The HMGA2 protein has experimentally been linked to EMT and cancer stemness. Recent studies imply that tumour-stroma interactions regulate these features and thereby contribute to tumour aggressiveness. METHODS: We analysed 253 cases of pancreatic ductal adenocarcinoma (PDAC) and 155 cases of ampullary adenocarcinoma (AAC) for HMGA2 expression by IHC. The data were correlated with stroma abundance and supplemented by experimental studies. RESULTS: HMGA2 acts as an independent prognostic marker associated with a significantly shorter overall survival in both tumour types. Overall, HMGA2-positivity was more frequent in patients with PDAC than with AAC. The HMGA2 status in tumour cells significantly correlated with the abundance of PDGFRß-defined stroma cells. In vivo co-injection of Panc-1 cancer cells with pancreatic stellate cells increased tumour growth in a manner associated with increased HMGA2 expression. Furthermore, in vitro treatment of Panc-1 with conditioned media from PDGF-BB-activated stellate cells increased their ability to form tumour spheroids. CONCLUSIONS: This study identifies HMGA2 expression in tumour cells as an independent prognostic marker in PDAC and AAC. Correlative data analysis gives novel tissue-based evidence for a heterotypic cross-talk with stroma cells as a possible mechanism for HMGA2 induction, which is further supported by experimental models.
[Mh] Termos MeSH primário: Adenocarcinoma/metabolismo
Carcinoma Ductal Pancreático/metabolismo
Neoplasias do Ducto Colédoco/metabolismo
Proteína HMGA2/metabolismo
Neoplasias Pancreáticas/metabolismo
[Mh] Termos MeSH secundário: Adenocarcinoma/patologia
Idoso
Ampola Hepatopancreática
Animais
Carcinoma Ductal Pancreático/patologia
Linhagem Celular Tumoral
Neoplasias do Ducto Colédoco/patologia
Feminino
Seres Humanos
Imuno-Histoquímica
Masculino
Camundongos
Camundongos SCID
Meia-Idade
Análise Multivariada
Estadiamento de Neoplasias
Transplante de Neoplasias
Neoplasias Pancreáticas/patologia
Células Estreladas do Pâncreas/metabolismo
Prognóstico
Receptor beta de Fator de Crescimento Derivado de Plaquetas/metabolismo
Reação em Cadeia da Polimerase Via Transcriptase Reversa
Células Estromais/metabolismo
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (HMGA2 Protein); EC 2.7.10.1 (Receptor, Platelet-Derived Growth Factor beta)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170520
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2017.140


  6 / 4336 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28518410
[Au] Autor:Acharya A; Markar SR; Sodergren MH; Malietzis G; Darzi A; Athanasiou T; Khan AZ
[Ad] Endereço:Division of Surgery, Department of Surgery and Cancer, St Mary's Hospital, Imperial College, London, UK.
[Ti] Título:Meta-analysis of adjuvant therapy following curative surgery for periampullary adenocarcinoma.
[So] Source:Br J Surg;104(7):814-822, 2017 Jun.
[Is] ISSN:1365-2168
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Periampullary cancers are uncommon malignancies, often amenable to surgery. Several studies have suggested a role for adjuvant chemotherapy and chemoradiotherapy in improving survival of patients with periampullary cancers, with variable results. The aim of this meta-analysis was to determine the survival benefit of adjuvant therapy for periampullary cancers. METHODS: A systematic review was undertaken of literature published between 1 January 2000 and 31 December 2015 to elicit and analyse the pooled overall survival associated with the use of either adjuvant chemotherapy or chemoradiotherapy versus observation in the treatment of surgically resected periampullary cancer. Included articles were also screened for information regarding stage, prognostic factors and toxicity-related events. RESULTS: A total of 704 titles were screened, of which 93 full-text articles were retrieved. Fourteen full-text articles were included in the study, six of which were RCTs. A total of 1671 patients (904 in the control group and 767 who received adjuvant therapy) were included. The median 5-year overall survival rate was 37·5 per cent in the control group, compared with 40·0 per cent in the adjuvant group (hazard ratio 1·08, 95 per cent c.i. 0·91 to 1·28; P = 0·067). In 32·2 per cent of patients who had adjuvant therapy, one or more WHO grade 3 or 4 toxicity-related events were noted. Advanced T category was associated worse survival (regression coefficient -0·14, P = 0·040), whereas nodal status and grade of differentiation were not. CONCLUSION: This systematic review found no associated survival benefit for adjuvant chemotherapy or chemoradiotherapy in the treatment of periampullary cancer.
[Mh] Termos MeSH primário: Adenocarcinoma/tratamento farmacológico
Adenocarcinoma/cirurgia
Ampola Hepatopancreática/cirurgia
Neoplasias do Ducto Colédoco/tratamento farmacológico
Neoplasias do Ducto Colédoco/cirurgia
Neoplasias Duodenais/tratamento farmacológico
Neoplasias Duodenais/cirurgia
[Mh] Termos MeSH secundário: Adenocarcinoma/mortalidade
Quimiorradioterapia Adjuvante
Quimioterapia Adjuvante
Neoplasias do Ducto Colédoco/mortalidade
Neoplasias Duodenais/mortalidade
Seres Humanos
Taxa de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170519
[St] Status:MEDLINE
[do] DOI:10.1002/bjs.10563


  7 / 4336 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28505002
[Au] Autor:Xue Y; Reid MD; Balci S; Quigley B; Muraki T; Memis B; Xia J; Hacihasanoglu E; Bedolla G; Pehlivanoglu B; Kim GE; Tajiri T; Ohike N; Aneja R; Krasinskas AM; Adsay V
[Ad] Endereço:*Department of Pathology, Emory University School of Medicine Departments of †Mathematics and Statistics ¶Biology, Georgia State University, Atlanta, GA ‡Department of Pathology, University of California San Francisco, San Francisco, CA §Department of Pathology, Tokai University Hachioji Hospital, Tokyo ∥Department of Pathology, Showa University Fujigaoka Hospital, Yokohama, Japan.
[Ti] Título:Immunohistochemical Classification of Ampullary Carcinomas: Critical Reappraisal Fails to Confirm Prognostic Relevance for Recently Proposed Panels, and Highlights MUC5AC as a Strong Prognosticator.
[So] Source:Am J Surg Pathol;41(7):865-876, 2017 Jul.
[Is] ISSN:1532-0979
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Recently, immunohistochemistry-based classifications of ampullary carcinomas have been proposed (Ang and colleagues [PMID: 24832159]; Chang and colleagues [PMID: 23439753]). In this study, the prognostic value of Ang/Chang panel markers (CK20, MUC1, MUC2, CDX2) as well as other markers (CK7, MUC5AC, and MUC6) were tested on full-faced sections of 136 ampullary carcinoma resections with substantial (>5 mm) invasion. Immunohistochemistry was correlated with both histologic classification (intestinal [INT], pancreatobiliary [PB], or nontubular based on ≥3/5 observer agreement) and clinical outcome. No prognostic correlation was found with MUC1, CDX2, MUC2 or CK20 despite testing with different quantitative cutoffs. CK7 and CK20 were nonspecific. Ang classification had reasonable correlation with histologic subclassification of tubular cases as INT versus PB with high specificity but low sensitivity and ambiguous category was large (29%) and included also some classical cases. Prognostically, Ang classification approached but did not reach statistical significance, even when their large "ambiguous" group was eliminated and only tubular cases were analyzed (Ang-INT vs. Ang-PB; P=0.08). The Chang panel, in which the definition of the INT subcategory is not clearly defined, only marginally reached prognostic significance when tested as MUC1+/CDX2- versus MUC1-/CDX2+ and only by Wilcoxon test (P=0.0485) but 31% of the cases were "unclassifiable." The only individual marker that was found to have direct and strong correlation with the clinical outcome was MUC5AC (not used in the Ang or Chang panels), with statistically significant survival differences found with various cutoffs tested (for 20% cutoff, 5-y survival, 68% vs. 31%; P=0.0002). In addition, MUC5AC significantly stratified the histologically PB and INT cases (P=0.01 and 0.03, respectively), as well as Ang's ambiguous and Chang's unclassified cases (P=0.006 and 0.007, respectively). In conclusion, the widely used putative lineage markers, MUC1/MUC2/CK7/CK20/CDX2, do not seem to have direct/significant prognostic correlation either individually or in combination of Ang and Chang panels. Ang panel is helpful as an adjunct in determining the cell lineage with a few caveats. MUC5AC proves to be a significant independent prognosticator and should be incorporated into evaluation of ampullary carcinomas.
[Mh] Termos MeSH primário: Adenocarcinoma/diagnóstico
Ampola Hepatopancreática/metabolismo
Biomarcadores Tumorais/metabolismo
Neoplasias do Ducto Colédoco/diagnóstico
Mucina-5AC/metabolismo
[Mh] Termos MeSH secundário: Adenocarcinoma/metabolismo
Adenocarcinoma/mortalidade
Adenocarcinoma/patologia
Adulto
Idoso
Idoso de 80 Anos ou mais
Ampola Hepatopancreática/patologia
Neoplasias do Ducto Colédoco/metabolismo
Neoplasias do Ducto Colédoco/mortalidade
Neoplasias do Ducto Colédoco/patologia
Feminino
Seguimentos
Seres Humanos
Imuno-Histoquímica
Masculino
Meia-Idade
Mucina-6/metabolismo
Prognóstico
Análise de Sobrevida
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers, Tumor); 0 (MUC5AC protein, human); 0 (MUC6 protein, human); 0 (Mucin 5AC); 0 (Mucin-6)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170913
[Lr] Data última revisão:
170913
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170516
[St] Status:MEDLINE
[do] DOI:10.1097/PAS.0000000000000863


  8 / 4336 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28417289
[Au] Autor:Tampi CS; Nilkanth S; Jagannath P
[Ad] Endereço:Department of Histopathology, Lilavati Hospital and Research Centre, A-791, Bandra Reclamation, Mumbai, 400 050, India. chandralekhatampi@gmail.com.
[Ti] Título:Reporting the margin in pancreaticoduodenectomies: R0 versus R1.
[So] Source:Indian J Gastroenterol;36(2):81-87, 2017 Mar.
[Is] ISSN:0975-0711
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:AIM: This study was conducted to analyze the changes in margin positivity in pancreaticoduodenectomies, on using a standardized protocol, which bread loafs the pancreas and duodenum in the axial plane for adenocarcinomas arising in the pancreatic head, ampulla, terminal common bile duct (CBD), and duodenum, and then to assess whether these tumor subsets involve the margins in different ways. METHODS: The analysis was performed on 70 consecutive specimens, the pre-protocol specimens serving as the control group. RESULTS AND CONCLUSIONS: Tumors originating from the pancreatic head, ampulla, terminal CBD, and duodenum showed a consistent increase in their R1 incidence, post-protocol. Ampullary tumors showed the greatest upward change in R1 positivity. The highest incidence of margin positivity was seen in pancreatic head adenocarcinomas (80%), then distal CBD tumors (60%), and finally the ampullary tumors (39%). In pancreatic head adenocarcinomas, R1 increased from 55% to 80%, distal CBD from 50% to 60%, and ampullary from 17% to 39%. Duodenal adenocarcinomas had no R1 in both pre- and post-protocol groups. The tumors also had different patterns of margin involvement. Ampullary tumors involved only the posterior margin, pancreatic adenocarcinomas involved the superior mesenteric vein (SMV) groove more often than the posterior margin, and distal CBD tumors involved the posterior margin and SMV groove equally. The size of the tumor made a significant difference in pancreatic head carcinomas with tumor size less than or equal to 2 cm, showing an R1 incidence of 38%, while those above 2 cm had an R1 incidence of 68%.
[Mh] Termos MeSH primário: Adenocarcinoma/cirurgia
Carcinoma/cirurgia
Neoplasias do Ducto Colédoco/cirurgia
Neoplasias Duodenais/cirurgia
Margens de Excisão
Neoplasias Pancreáticas/cirurgia
Pancreaticoduodenectomia/métodos
[Mh] Termos MeSH secundário: Adenocarcinoma/patologia
Ampola Hepatopancreática
Carcinoma/patologia
Neoplasias do Ducto Colédoco/patologia
Neoplasias Duodenais/patologia
Seres Humanos
Neoplasias Pancreáticas/patologia
Pancreaticoduodenectomia/normas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170419
[St] Status:MEDLINE
[do] DOI:10.1007/s12664-017-0742-8


  9 / 4336 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28317689
[Au] Autor:Carr-Locke DL
[Ad] Endereço:Division of Digestive Diseases, Mount Sinai Beth Israel Medical Center, New York, New York, USA.
[Ti] Título:Endoscopic papillectomy for adenoma: To inject or not to inject? That is no longer the question.
[So] Source:Gastrointest Endosc;85(4):756-757, 2017 04.
[Is] ISSN:1097-6779
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Ampola Hepatopancreática
Neoplasias do Ducto Colédoco
[Mh] Termos MeSH secundário: Adenoma
Endoscopia
Seres Humanos
[Pt] Tipo de publicação:EDITORIAL; COMMENT
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170321
[St] Status:MEDLINE


  10 / 4336 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28292513
[Au] Autor:Amr B; Miles G; Shahtahmassebi G; Roobottom C; Stell DA
[Ad] Endereço:Peninsula HPB Unit, Derriford Hospital, Plymouth PL6 8DH, UK; Peninsula Schools of Medicine and Dentistry, Plymouth University, Plymouth PL6 8BU, UK.
[Ti] Título:Systematic evaluation of radiological findings in the assessment of resectability of peri-ampullary cancer by CT using different contrast phase protocols.
[So] Source:Clin Radiol;72(8):691.e11-691.e17, 2017 Aug.
[Is] ISSN:1365-229X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:AIMS: To determine the relative significance of radiological signs in determining the resectability of peri-ampullary cancer (PC) and to assess the value of multi-phase imaging in detecting these findings. MATERIALS AND METHODS: Blinded, double re-reporting of preoperative imaging from five hospitals was undertaken of 411 patients undergoing surgery for PC over an 8-year period, of whom 119 patients were found to be inoperable at the time of surgery. RESULTS: The median tumour size was 26.7 mm and the proportion of patients reported to have regional lymphadenopathy (RL), venous (VI) and arterial involvement (AI) was 24.7%, 11.5%, and 3.9%, respectively and was similar regardless of the number of contrast phases undertaken. Significant associations were, however, noted between individual risk factors: VI was closely associated with tumour size (p=0.002) and AI (p<0.0001). In multivariate analysis AI, VI, and RL were independently associated with resectability (relative risk of resection=0.05, 0.31, and 0.51, respectively). Tumour size, however, was not associated with resectability when VI was included in the multivariate model. CONCLUSIONS: The use of multiple vascular contrast phases has no measureable impact on the rate of determination of tumour resectability of PC. In preoperative staging, AI is the most significant adverse finding for resectability. Large tumour diameter is not an adverse finding in isolation from other risk factors.
[Mh] Termos MeSH primário: Adenocarcinoma/diagnóstico por imagem
Adenocarcinoma/cirurgia
Ampola Hepatopancreática
Neoplasias do Ducto Colédoco/diagnóstico por imagem
Neoplasias do Ducto Colédoco/cirurgia
Neoplasias Duodenais/diagnóstico por imagem
Neoplasias Duodenais/cirurgia
Neoplasias Pancreáticas/diagnóstico por imagem
Neoplasias Pancreáticas/cirurgia
Tomografia Computadorizada por Raios X/métodos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Protocolos Clínicos
Feminino
Seres Humanos
Masculino
Meia-Idade
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170720
[Lr] Data última revisão:
170720
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE



página 1 de 434 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde